In this chapter, we describe the role of passive immunity in the protection of the naïve host, discuss the parameters involved with successful immunotherapy, and provide examples of protective efficacy in animal models as well as in human clinical studies. TABLE 8.1. Licensed U.S. Antibody ...
While active immunization elicits a lasting immune response by the body, passive immunotherapy transiently equips the body with exogenously generated immunological effectors in the form of either target-specific antibodies or lymphocytes functionalized with target-specific receptors. In either case, administrat...
PEPTIDE, DENDRITIC CELL, CYTOTOXIC T-CELL, LEUKEMIA VACCINE, AND PASSIVE IMMUNOTHERAPY AGENT FOR LEUKEMIAPROBLEM TO BE SOLVED: To provide novel means which can contribute to application of immunotherapy for leukemia treatment, and to provide a screening method thereof.MATSUSHITA MAIKO...
The possibility that toxic tau seeding species containing the MTBR are extracellular and transmissible in human brain opens up the prospect of therapeutic intervention through immunotherapy. Since the first preclinical report of active immunisation in transgenic mice [5], this area of tau research has ...
Patients with recurring illnesses did not react to immunotherapy, irrespective of their PD-L1/MHC class I expression levels, implying that these immunostaining methods might not be reliable predictors in this specific disease context. MHC class I expression is subclinally lost in ovarian cancers, ...